Roivant Sciences Share Price (NASDAQ: ROIV)

$11.94

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Roivant Sciences Stock chart to analyse performance

Roivant Sciences stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$11.85
Today's High:$12.03
$11.94
0.75%
Downside
Day's Volatility :1.46%
Upside
0.71%
52 Weeks Low:$8.73
52 Weeks High:$13.06
$11.94
26.88%
Downside
52 Weeks Volatility :33.13%
Upside
8.54%

Roivant Sciences Stock Returns

Period	Roivant Sciences Ltd.	Sector (Health Care)	Index (Russel 2000)
3 Months	6.89%	3.6%	0.0%
6 Months	17.4%	-7.7%	0.0%
1 Year	1.44%	-12.6%	0.0%
3 Years	235.39%	9.5%	-4.7%

Roivant Sciences Ltd. Key Stats

Check Roivant Sciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$11.94
Open	$11.94
Today's High	$12.025
Today's Low	$11.85
Market Capitalization	$8.2B
Today's Volume	$4.5M
52 Week High	$13.055
52 Week Low	$8.73
Revenue TTM	$23.2M
EBITDA	$-1.1B
Earnings Per Share (EPS)	$-1.09
Profit Margin	0.0%
Quarterly Earnings Growth YOY	-0.96%
Return On Equity TTM	-18.15%

Stock Returns calculator for Roivant Sciences Stock including INR - Dollar returns

The Roivant Sciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Roivant Sciences investment value today

Current value as on today

₹1,06,728

Returns

₹6,728

(+6.73%)

Returns from Roivant Sciences Stock

₹1,444 (+1.44%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Roivant Sciences Stock

21%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Roivant Sciences Stock from India on INDmoney has increased by 21% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Roivant Sciences Ltd.

Name
Holdings %
Name
Holdings %
Qvt Financial LP
9.64%
SB INVESTMENT ADVISERS (UK) LTD
8.78%
FMR Inc
7.57%
BlackRock Inc
6.10%
Vanguard Group Inc
5.76%
Morgan Stanley - Brokerage Accounts
5.26%

Analyst Recommendation on Roivant Sciences Stock

Rating

Trend

Buy

88%Buy

11%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Roivant Sciences(by analysts ranked 0 to 5 stars)

Roivant Sciences Share Price Target

What analysts predicted

Upside of 43.31%

Target:

$17.11

Current:

$11.94

Roivant Sciences share price target is $17.11, a slight Upside of 43.31% compared to current price of $11.94 as per analysts' prediction.

Roivant Sciences Stock Insights

Price Movement
In the last 3 years, ROIV stock has moved up by 241.1%
Decreasing Revenue
Revenue is down for the last 3 quarters, 9.01M → 2.17M (in $), with an average decrease of 43.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 169.38M → -223.35M (in $), with an average decrease of 115.0% per quarter
ROIV vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 72.3%
Price to Sales
ForROIV every $1 of sales, investors are willing to pay $361.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Roivant Sciences Ltd. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Revenue	$67.7M	↑ 2812.61%
Net Income	$1.2B	↓ 215.22%
Net Profit Margin	1.8K%	↑ 46608.72%

	FY21	Y/Y Change
Revenue	$23.8M	↓ 64.85%
Net Income	$-809.2M	↓ 167.41%
Net Profit Margin	-3.4K%	↓ 5174.43%

	FY22	Y/Y Change
Revenue	$55.3M	↑ 132.34%
Net Income	$-845.3M	↑ 4.45%
Net Profit Margin	-1.5K%	↑ 1871.97%

	FY23	Y/Y Change
Revenue	$61.3M	↑ 10.84%
Net Income	$-1.0B	↑ 19.37%
Net Profit Margin	-1.6K%	↓ 117.7%

	FY24	Y/Y Change
Revenue	$124.8M	↑ 103.65%
Net Income	$4.3B	↓ 531.0%
Net Profit Margin	3.5K%	↑ 5131.45%

	FY25	Y/Y Change
Revenue	$29.1M	↓ 76.72%
Net Income	$-172.0M	↓ 103.95%
Net Profit Margin	-591.96%	↓ 4076.82%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$28.9M	↓ 22.11%
Net Income	$-151.1M	↓ 102.97%
Net Profit Margin	-522.35%	↓ 14243.9%

	Q2 FY24	Q/Q Change
Revenue	$55.1M	↑ 90.57%
Net Income	$95.3M	↓ 163.06%
Net Profit Margin	172.85%	↑ 695.2%

	Q3 FY24	Q/Q Change
Revenue	$4.5M	↓ 91.88%
Net Income	$-230.2M	↓ 341.54%
Net Profit Margin	-5.1K%	↓ 5316.63%

	Q4 FY24	Q/Q Change
Revenue	$9.0M	↑ 101.52%
Net Income	$169.4M	↓ 173.59%
Net Profit Margin	1.9K%	↑ 7022.03%

	Q1 FY25	Q/Q Change
Revenue	$7.6M	↓ 16.06%
Net Income	$-206.5M	↓ 221.9%
Net Profit Margin	-2.7K%	↓ 4605.79%

	Q2 FY25	Q/Q Change
Revenue	$2.2M	↓ 71.33%
Net Income	$-223.4M	↑ 8.18%
Net Profit Margin	-10.3K%	↓ 7565.32%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Profit	$66.6M	↑ 3774.16%

	FY21	Y/Y Change
Profit	$21.7M	↓ 67.34%

	FY22	Y/Y Change
Profit	$46.3M	↑ 113.08%

	FY23	Y/Y Change
Profit	$48.2M	↑ 3.96%

	FY24	Y/Y Change
Profit	$96.8M	↑ 101.09%

	FY25	Y/Y Change
Profit	$28.1M	↓ 70.94%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$24.5M	↓ 26.75%

	Q2 FY24	Q/Q Change
Profit	$51.2M	↑ 108.64%

	Q3 FY24	Q/Q Change
Profit	$4.2M	↓ 91.71%

	Q4 FY24	Q/Q Change
Profit	$8.8M	↑ 106.53%

	Q1 FY25	Q/Q Change
Profit	$6.0M	↓ 31.7%

	Q2 FY25	Q/Q Change
Profit	$2.0M	↓ 66.3%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Operating Cash Flow	$-761.8M	↓ 25.62%
Investing Cash Flow	$1.7B	↓ 3041.94%
Financing Cash Flow	$217.2M	↓ 71.69%

	FY21	Y/Y Change
Operating Cash Flow	$-552.1M	↓ 27.52%
Investing Cash Flow	$-31.7M	↓ 101.87%
Financing Cash Flow	$456.3M	↑ 110.1%

	FY22	Y/Y Change
Operating Cash Flow	$-677.7M	↑ 22.75%
Investing Cash Flow	$303.3M	↓ 1056.71%
Financing Cash Flow	$306.8M	↓ 32.76%

	FY23	Y/Y Change
Operating Cash Flow	$-843.4M	↑ 24.44%
Investing Cash Flow	$-44.3M	↓ 114.6%
Financing Cash Flow	$499.5M	↑ 62.8%

	FY24	Y/Y Change
Operating Cash Flow	$-765.3M	↓ 9.26%
Investing Cash Flow	$5.2B	↓ 11854.55%
Financing Cash Flow	$419.4M	↓ 16.04%

	FY25	Y/Y Change
Operating Cash Flow	$-839.5M	↑ 9.69%
Investing Cash Flow	$-1.8B	↓ 133.94%
Financing Cash Flow	$-1.2B	↓ 390.87%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-108.5M	↓ 48.46%
Investing Cash Flow	$6.9M	↓ 99.87%
Financing Cash Flow	$-32.6M	↓ 113.79%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-192.8M	↑ 77.79%
Investing Cash Flow	$-965.0K	↓ 113.93%
Financing Cash Flow	$-660.6M	↑ 1924.94%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-266.8M	↑ 38.36%
Investing Cash Flow	$-3.3B	↑ 341205.08%
Financing Cash Flow	$-109.1M	↓ 83.49%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-207.3M	↓ 22.32%
Investing Cash Flow	$454.1M	↓ 113.79%
Financing Cash Flow	$-273.0M	↑ 150.24%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-172.6M	↓ 16.74%
Investing Cash Flow	$1.1B	↑ 136.57%
Financing Cash Flow	$-177.2M	↓ 35.1%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-204.4M	↑ 18.44%
Investing Cash Flow	$-1.1B	↓ 201.07%
Financing Cash Flow	$-187.8M	↑ 5.99%

Roivant Sciences Technicals Summary

Sell

Neutral

Buy

Roivant Sciences is currently in a neutral trading position according to technical analysis indicators.

Roivant Sciences Ltd. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Roivant Sciences Ltd.	5.57%	17.4%	1.44%	235.39%	27.7%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Roivant Sciences Ltd.	1.97	NA	NA	-0.57	-0.18	-0.13	NA	6.37
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Roivant Sciences Ltd.	Buy	$8.2B	27.7%	1.97	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Roivant Sciences Ltd.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Organization	Roivant Sciences
Employees	750
CEO	Dr. Eric Venker M.D., Pharm.D.
Industry	Financial

Key Management of Roivant Sciences Ltd.

Name	Title
Mr. Matthew Gline	CEO & Director
Dr. Eric Venker M.D., Pharm.D.	President & CEO of Immunovant
Dr. Mayukh Sukhatme M.D.	President, Chief Investment Officer & Director
Mr. Richard Pulik	Chief Financial Officer
Ms. Jennifer Humes	Chief Accounting Officer
Dr. Frank M. Torti M.B.A., M.D.	President & Vant Chair
Dr. Huafeng Xu Ph.D.	Chief Technology Officer
Mr. Drew Kramer	Chief Information Officer
Mr. Josh Chen J.D.	General Counsel
Ms. Kelly Graff	Head of People

Important FAQs about investing in ROIV Stock from India :

What is Roivant Sciences share price today?

Roivant Sciences share price today is $11.94 as on August 30, 2025 at 1:29 am IST at the close of the market. Roivant Sciences share today touched a day high of $12.03 and a low of $11.85.

What is the 52 week high and 52 week low for Roivant Sciences share?

Roivant Sciences share touched a 52 week high of $13.06 and a 52 week low of $8.73. Roivant Sciences stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $11.94, lower by 8.54% versus the 52 week high.

How to invest in Roivant Sciences Stock (ROIV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Roivant Sciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Roivant Sciences Shares that will get you 0.1256 shares as per Roivant Sciences share price of $11.94 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Roivant Sciences Stock (ROIV) from India?

Indian investors can start investing in Roivant Sciences (ROIV) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Roivant Sciences stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Roivant Sciences share’s latest price of $11.94 as on August 30, 2025 at 1:29 am IST, you will get 0.8375 shares of Roivant Sciences. Learn more about fractional shares .

What are the returns that Roivant Sciences has given to Indian investors in the last 5 years?

Roivant Sciences stock has given 27.7% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?